Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Femasys Inc. - Common Stock (NQ:FEMY)

3.850 +0.580 (+17.74%)
Streaming Delayed Price Updated: 12:47 PM EDT, Jul 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Femasys Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Femasys Regains Compliance with Nasdaq Listing Requirements
From Femasys Inc.
Via GlobeNewswire
News headline image
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More ↗
Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market. 
Via The Motley Fool
Topics Regulatory Compliance
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
News headline image
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
-- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices -- 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
Expanding commercialization of first-line fertility treatment in the OB/GYN office to increase patient access 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
-- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval -- 
From Femasys Inc.
Via GlobeNewswire
Traders are paying attention to the gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
-- Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe -- 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient population 
From Femasys Inc.
Via GlobeNewswire
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
From Femasys Inc.
Via GlobeNewswire
News headline image
Wondering what's happening in today's after-hours session? ↗
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
PMCB Stock Jumps 25% After Company Sells Stake In Femasys ↗
PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Femasys Announces Third Quarter Financial Results for 2025
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe
From Femasys Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing ↗
Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device. 
Via Stocktwits
News headline image
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
From Femasys Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.